Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to share encouraging preclinical results presented at the American Association for Cancer Research, highlighting the company’s novel therapeutic candidate TNX-1700 for gastric cancer. In the study, a murine fusion protein (mTFF2-MSA) was tested, modeling the human fusion version TFF2-HSA currently under development as TNX-1700. Dr. Lederman explained that combining mTFF2-MSA with anti-PD1 immunotherapy significantly reduced tumor immunosuppression in animal models. Specifically, the therapy decreased immunosuppressive neutrophils and cancer-induced granulopoiesis, while stimulating CD8+ T-cell responses that helped inhibit tumor progression. The study also revealed a negative correlation between TFF2 expression and PMN-MDSC levels in gastric cancer patients, supporting the clinical relevance of TFF2 modulation in immuno-oncology. Tonix plans to continue advancing TNX-1700 as a first-in-class fusion protein therapeutic for hard-to-treat cancers. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #TonixPharmaceuticals #TNX1700 #GastricCancer #CancerResearch #Immunotherapy #PD1Blockers #AACR2025 #BiotechNews #OncologyInnovation #CancerTreatment